Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D02FTV
|
|||
| Former ID |
DIB003095
|
|||
| Drug Name |
INGN-241
|
|||
| Synonyms |
AD-IL-24, Introgen; AD-mda-7, Introgen; Adenovirus-IL-24, Introgen; Adenovirus-mda-7, Introgen
Click to Show/Hide
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 2 | [1] | |
| Company |
Multivir; Introgen Therapeutics
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Interleukin-24 (IL24) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| Jak-STAT signaling pathway | ||||
| NetPath Pathway | IL-7 Signaling Pathway | |||
| IL2 Signaling Pathway | ||||
| Pathway Interaction Database | IL23-mediated signaling events | |||
| WikiPathways | Senescence and Autophagy in Cancer | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00116363) Safety and Efficacy Study of INGN 241 Gene Therapy in Patients With In Transit Melanoma. U.S. National Institutes of Health. | |||
| REF 2 | Intratumoral injection of INGN 241, a nonreplicating adenovector expressing the melanoma-differentiation associated gene-7 (mda-7/IL24): biologic outcome in advanced cancer patients. Mol Ther. 2005 Jan;11(1):160-72. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.